Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Cash from Operations (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Cash from Operations for 4 consecutive years, with 2109072.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 25.45% to 2109072.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 6794783.0, a 66.8% decrease, with the full-year FY2024 number at 5648088.0, down 24.33% from a year prior.
  • Cash from Operations was 2109072.0 for Q3 2025 at 60 Degrees Pharmaceuticals, down from 1450128.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 63668.0 in Q4 2023 to a low of 3753074.0 in Q3 2023.
  • A 4-year average of 1209276.92 and a median of 1188212.0 in 2024 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 55.2% in 2024; the steepest drop was 2473.06% in 2024.
  • 60 Degrees Pharmaceuticals' Cash from Operations stood at 65977.0 in 2022, then rose by 3.5% to 63668.0 in 2023, then tumbled by 2473.06% to 1638217.0 in 2024, then fell by 28.74% to 2109072.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Cash from Operations are 2109072.0 (Q3 2025), 1450128.0 (Q2 2025), and 1597366.0 (Q1 2025).